OSTX — OS Therapies Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1795091 ·
Last close
$1.66
Market Cap
$77.70M
52W High
$2.25
52W Low
$1.15
ADV30
644,897
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -8,575,612 | -8,632,386 | 9,897,313 | 205,035 | 21,811,948 |
| Mar 2026 | 0 | — | -10,167,938 | -10,396,831 | 7,299,236 | 917,552 | 18,123,474 |
| Dec 2025 | 0 | — | -11,987,892 | -13,460,833 | 6,839,534 | 269,830 | 12,935,165 |
| Sep 2025 | 0 | — | -6,879,595 | -6,879,530 | 8,953,251 | 1,876,626 | 5,316,056 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,360,230
Investing CF
$-292,787
Financing CF
$13,599,562
CapEx
$-466,423
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.85
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,583,050
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-35,198,472
Pretax Income TTM
$-35,273,816
Interest Exp TTM
$75,344
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,705,701 | -28,753,844 | 6,839,534 | 12,935,165 | -6,095,631 | -14,238,576 |
| Dec 2024 | 0 | -6,813,846 | -8,882,938 | 5,538,797 | 8,805,335 | -3,266,538 | -7,282,295 |
| Dec 2023 | 0 | -4,342,645 | -7,791,582 | 798,082 | 24,814,297 | -24,016,215 | -3,006,967 |
| Dec 2022 | 0 | -4,446,299 | -6,254,685 | 509,105 | 18,066,333 | -17,557,228 | -3,792,580 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GANX | Gain Therapeutics, Inc. | $77.69M | $1.78 | — |
| INCR | Intercure Ltd. | $78.17M | $5.21 | — |
| ZOMDF | Zomedica Corp. | $78.40M | $0.08 | — |
| LFVN | Lifevantage Corp | $78.42M | $6.26 | — |
| IBIO | iBio, Inc. | $76.53M | $1.19 | — |
News headlines (Yahoo Finance, 1h cache)
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
2026-09-24 12:22 · Yahoo
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
2026-09-21 10:30 · Yahoo
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
2026-09-17 10:00 · Yahoo
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
2026-09-15 11:46 · Yahoo
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
2026-09-08 10:00 · Yahoo
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
2026-09-02 11:20 · Yahoo
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
2026-08-17 11:40 · Yahoo
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic
2026-08-13 12:45 · Yahoo
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
2026-07-08 13:00 · Yahoo
OS Therapies Third Quarter 2026 Corporate Outlook
2026-07-06 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.